Financial Performance - The company reported a revenue of 1.2 billion RMB for the fiscal year 2023, representing a year-over-year growth of 15%[21]. - The company's operating revenue for 2024 is reported at ¥2,013,856,558, a decrease of 5.02% compared to ¥2,120,251,604 in 2023[26]. - Net profit attributable to shareholders for 2024 is ¥142,397,376, reflecting a significant decline of 68.67% from ¥454,437,474 in 2023[26]. - The net profit after deducting non-recurring gains and losses is ¥110,319,389.71 for 2024, down 75.07% from ¥442,470,555 in 2023[26]. - The company’s total revenue for 2024 was approximately ¥2.01 billion, a decrease of 5.02% compared to ¥2.12 billion in 2023[99]. - The revenue from ultrasound products was ¥1.18 billion, accounting for 58.75% of total revenue, with a year-on-year decline of 3.26%[99]. - The company achieved a gross margin of 63.78% in the medical device sector, down 3.93% from the previous year[100]. - International sales contributed ¥970.16 million, representing 48.17% of total revenue, with a growth of 3.27% year-on-year[99]. Research and Development - R&D and sales expenses increased year-on-year, with R&D expenses accounting for approximately 20% of current operating revenue, indicating a high level of strategic investment in new product lines[5]. - Research and development expenses increased by 10% to 120 million RMB, focusing on innovative medical technologies[21]. - The company has invested in R&D with expenditures of 328.96 million, 384.26 million, and 472.93 million yuan for the years 2022, 2023, and 2024, respectively, representing 18.66%, 18.12%, and 23.48% of total revenue[68]. - The company holds a total of 1,035 patents, including invention and utility model patents, and has been recognized as a "National High-tech Enterprise" since 2009, reflecting its strong R&D capabilities[68]. - The number of R&D personnel increased by 16.48% to 841, with a higher proportion of master's degree holders at 50.4%[109]. - The company is focusing on innovative medical devices, with several products classified as innovative medical devices under review[116]. Product Development and Launches - The company plans to rely on high-end and diversified product development strategies to continuously launch more competitive products and expand market share[4]. - New product launches include an advanced ultrasound diagnostic device expected to enhance imaging quality by 30%[21]. - The company launched high-end ultrasound machines S80 and P80 in 2024, marking a breakthrough in the high-end ultrasound field[54]. - The company has launched multiple new self-developed endoscopes, including various types of digestive and respiratory endoscopes, enhancing the user experience and aiming to elevate domestic endoscopy capabilities to handle more complex clinical scenarios[58]. - The company has introduced several new disposable medical devices intended for use with flexible endoscopes, including Disposable Needle Electrode, Disposable Coagulation Electrode, and Disposable Hot Biopsy Forceps, all classified as IIb devices[128]. Market Expansion - The company is expanding its market presence in Europe, targeting a 20% market share by the end of 2025[21]. - The company is actively expanding its minimally invasive surgical business and has introduced a team with extensive experience in surgical products and marketing[50]. - The company is expanding its market presence in Southeast Asia, targeting a 20% increase in sales in that region over the next fiscal year[196]. - The company has established a global marketing network covering nearly 170 countries and regions[82]. Strategic Initiatives - The company has initiated a strategic acquisition of a local competitor, which is projected to increase market penetration by 15%[21]. - The company has implemented several accounting policy changes effective January 1, 2024, including the adoption of new standards regarding the classification of current and non-current liabilities[27]. - The company has established a market value management plan approved on April 10, 2025, to enhance valuation[171]. - The "Quality and Return Dual Improvement" action plan has been implemented, focusing on share repurchase and high-end product launches[172]. Corporate Governance - The company has ensured compliance with corporate governance regulations, with a board of directors consisting of 7 members, including 3 independent directors[178]. - The company has established a performance evaluation and incentive mechanism for directors, supervisors, and senior management[181]. - The company operates independently from its controlling shareholder, ensuring no interference in decision-making[177]. Social Responsibility - The company’s efforts in social responsibility included providing free liver ultrasound examinations for patients with echinococcosis in western regions, contributing to the establishment of a comprehensive prevention and treatment system[95]. Financial Management - The cash inflow from investment activities in 2024 was CNY 1,015.99 million, an increase of 71.53% year-over-year, mainly due to increased redemptions of financial products[133]. - The cash outflow from investment activities surged to CNY 1,607.13 million, a significant increase of 295.70% compared to the previous year, primarily due to increased purchases of financial products[133]. - The total cash and cash equivalents decreased by CNY 202.67 million in 2024, a decline of 150.28% compared to the previous year, attributed to higher expenditures on financial products[134].

21世纪经济报道记者 杨坪 深圳报道 AI正在重构医疗产业的生产力。 2025 年两会政府工作报告提出，持续推进"人工智能+"行动，将数字技术与制造优势、市场优势更好结合起来。 刚刚闭幕的第91届中国国际医疗器械博览会（CMEF）上，人工智能成为最热门的话题。期间，来自全球30多个国家和地区的近5000家企业，展出了最新的 AI医疗尖端产品及服务。开立医疗，就是其中之一。 集采带动公司份额提升 开立医疗是国内医疗器械龙头企业，旗下有超声医学影像、软式内窥镜、微创外科和心血管介入多条产品矩阵。其中公司2023年国内超声影像诊断设备的市 占率排名第四，在国产品牌中排名第二；消化内镜在国内市场中，居国产品牌首位。 此前，受集采、医院招投标需求放缓等因素影响，国内医疗器械产业链经历较大波动。但从去年底开始，在大规模设备更新等政策推动下，行业景气度持续 回升。 今年1月，国家发展改革委、财政部发布《关于2025年加力扩围实施大规模设备更新和消费品以旧换新政策的通知》，明确提到直接向地方安排的资金总体 按照9:1的原则实行央地共担，东部、中部、西部地区中央承担比例分别为85%、90%、95%。 一季度，广东、河北、江苏、 ...

智通财经4月9日电，记者从开立医疗方面获悉，美国加征"对等关税"对公司影响不大，因为美国市场收 入在公司营业收入中的占比不到2%，且美国代理商已提前进行了适当备货。公司在海外布局多年、运 营较完善，近年来加强本地化建设，逐步在海外建立分公司。未来，公司会进一步加大海外市场投入， 重点在欧洲、俄罗斯、印度、拉美等地区拓展布局。（智通财经记者 何凡） 开立医疗回应美关税调整：公司美国市场收入占比不到2% ...

展会期间，超高端全身及妇产超声河图®S80、梦溪P80及高端智能便携超声天枢X11、天璇E11亮相， 产品搭载全新C-Field+天工智能平台，基于独有的场成像发射、自适应聚合重建技术，可获取更精准的 图像，同时基于XPUs混合硬件架构，为临床提供多科室智能解决方案。 在内镜诊疗领域，开立医疗新一代智慧内镜平台iEndo迎来首秀。该平台创新搭载独立GPU和超分辨成 像技术，搭配丰富镜种，塑造内外融合诊疗一体化智慧生态。 值得一提的是，在心血管介入领域，以临床需求为导向，开立医疗V-reader®血管内超声诊断系统和 SonoSound®导管组成的智能超宽频腔内影像方案，集造影和IVUS多模态影像联动、高帧频高速成像、 灵活操控部署模式、远程协同于一体，为医生提供更高效、易用的使用体验，推动了精准介入疗法的发 展和技术下沉。 本报讯 （记者王镜茹） 4月8日，第91届中国国际医疗器械博览会（CMEF）在国家会展中心（上海）开幕。深圳开立生物医疗 科技股份有限公司（以下简称"开立医疗"）携其AI专科解决方案及多款核心设备亮相，全方位彰显在智 慧医疗领域的前瞻性布局与深厚的自主创新实力。 依托自主研发的高端智能影像 ...

4月8日—11日，被誉为"全球医疗风向标"的第91届中国国际医疗器械博览会（CMEF）正式在国家会展中心（上海）举办，来自全球的近5000家企业围 绕"创新科技，智领未来"的主题，为全球医疗健康产业带来了最前沿的医疗科技与设备。 作为国产超声医学影像和医用内窥镜的双龙头企业，开立医疗本次以"智引浪潮 奔涌向新"为主题，携超声医学影像、内镜诊疗、微创外科和心血管介入四 大产品线的智慧新品及创新解决方案精彩亮相CMEF，全面展现各大产品线所打造的全新智慧诊疗生态。 新一代高端产品重磅亮相，四大产品线迎来全面升级 随着多年技术突破与覆盖领域逐步完善，开立医疗已初步构建涵盖超声医学影像、内镜诊疗、微创外科和心血管介入等领域的多产品线矩阵，持续引领国产 高端医疗设备创新突破。在本次CMEF上，开立医疗再度走在行业前沿，率先推出多款智能化水平更进一步的重磅新品，充分展现了公司强大的自研硬实 力。 在超声医学影像领域，开立医疗本次展出超高端全身超声新品河图®S80、超高端智能妇产超声新品梦溪TMP80。两大旗舰新品搭载全新C-Field+天工智能平 台，基于独有的场成像发射、自适应聚合重建技术，获取更精准、更高分辨率的图像 ...

最新一期业绩显示，2024年三季报，公司实现营业收入13.98亿元，同比-4.74%；净利润1.09亿元，同 比-66.01%，销售毛利率66.59%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)93开立医疗54.1828.954.22131.54亿行业平均 46.4650.224.93109.40亿行业中值33.0731.042.5248.44亿1硕世生物-1956.94-1956.941.2340.43亿2诺唯 赞-583.67-583.672.5299.23亿3博晖创新-305.50-188.093.3746.89亿4康泰医学-294.1934.523.0157.22亿5华 大基因-216.51236.822.24220.01亿6奥精医疗-121.42-121.421.5522.00亿7睿昂基因-83.80-83.801.3012.12亿 8热景生物-57.27-57.273.15102.65亿9华大智造-54.80-54.804.11328.30亿10中红医疗-54.40-37.010.8648.44 亿11天智航-46.58-46.584.8657.34亿 4月1日，开立医疗今日收盘30 ...

一、本次股东股份质押的基本情况 1、本次股份解除质押情况 证券代码：300633 证券简称：开立医疗 公告编号：2025-002 深圳开立生物医疗科技股份有限公司 关于控股股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳开立生物医疗科技股份有限公司（以下简称"公司"）近日收到公司 控股股东之一陈志强先生的通知，获悉其将所持有的公司部分股份办理了解除 质押及再质押手续，具体事项如下： 截至本公告披露日，公司控股股东陈志强先生、吴坤祥先生（一致行动 人）所持公司股份累计质押情况如下： | 股东 | 是否为控 股股东及 | 本次解除 质押股份 | 占其所 持股份 | 占公司 总股本 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 其一致行 动人 | 数量 | 比例 | 比例 | | | | | 陈志 | | | | | 2023-04- | 2025-03- | 中国银河 | | 强 | 是 | 3,000,000 | ...

Summary of the Conference Call for Kaili Medical Company Overview - Kaili Medical is a leading domestic enterprise in ultrasound and software, initially focused on ultrasound and expanded into soft endoscopy in 2012, becoming the market leader in soft endoscopy. [3][4] - The company has developed a comprehensive product layout from internal medicine to surgery, diagnosis to treatment, and equipment to consumables. [4][5] Key Insights and Arguments - **Market Recovery Expectations**: The bidding recovery in 2025 is expected to be better than in 2024, driven by the release of pent-up demand and improvements in the industry ecosystem. The ultrasound business is anticipated to recover more significantly due to equipment upgrade projects. [4][5] - **New Product Launches**: The new soft endoscope HHD650 has been approved and is expected to enter the market in the second half of the year, enhancing the 4K product line and potentially increasing market share. Additionally, the company has launched the 80 series high-end ultrasound equipment, integrating AI technology for obstetric applications. [4][6] - **Revenue Structure**: The company's revenue primarily comes from ultrasound (50%-60%) and medical software development (approximately 40%), with domestic revenue accounting for about 50% and overseas revenue for about 40%. [7] - **Market Position**: In the domestic ultrasound market, foreign companies hold significant shares, but domestic players like Mindray and Kaili have entered the top five, with Mindray holding a 32% market share in 2023 and Kaili at 7%. [4][8] - **Endoscopy Market Dynamics**: The domestic digestive endoscopy market is mainly dominated by Japanese companies, but domestic companies, including Kaili, are increasing their market share, with Anba holding around 45% and two domestic companies combined nearing 20%. [9] Additional Important Points - **Technological Innovations**: Kaili Medical has made significant technological advancements, such as applying CMOS chips in medical devices to break the long-standing monopoly of CCD sensors by Japanese companies. [10][11] - **AI Integration**: The integration of AI with ultrasound, such as the Fengyan technology for obstetric applications, has been clinically validated and approved, enhancing diagnostic accuracy and competitiveness. [12] - **Future Business Directions**: The company plans to expand into minimally invasive surgery and hardware-related emerging fields, aiming to enhance overall competitiveness and profitability. [13] - **Cardiovascular and Minimally Invasive Surgery Performance**: The company is still in the investment phase for its cardiovascular business, particularly in intravascular ultrasound (IVUS), with expectations of market penetration increasing as domestic alternatives and centralized procurement progress. [14][15] - **Outlook for 2025**: The outlook for Kaili Medical in 2025 is positive, with expectations of improved fundamentals, recovery in terminal bidding demand, and significant growth in ultrasound product sales due to equipment upgrade projects. [16]

Group 1 - Investment Rating: "Accumulate" (First Coverage) [1] - Core Viewpoint: The company is positioned to benefit from the ongoing medical equipment update policies, with expectations for performance recovery [6][7] - The company has established a multi-product line structure, with strong positions in ultrasound and endoscopy sectors [5][30] Group 2 - The company achieved a revenue of 2.12 billion yuan in 2023, with a year-on-year growth of 20.29% [23] - The forecasted revenue growth rates for 2024-2026 are -2.10%, 20.20%, and 21.14% respectively [7] - The company ranks fourth in the domestic ultrasound market and is among the top ten globally [44] Group 3 - The company has a strong focus on R&D, with a research expense of 3.38 billion yuan in Q1-Q3 2024, representing a year-on-year increase of 28.33% [36] - The company has established seven global R&D centers to enhance its technological capabilities [22] - The company’s ultrasound products have seen a compound annual growth rate (CAGR) of 15.98% from 2020 to 2023 [30] Group 4 - The company’s endoscopy business has a market share of 11.80% in 2023, ranking first among domestic brands [56] - The company has introduced several innovative endoscopic products, including the HD-580 series, which significantly improves image quality [61] - The company is actively expanding its market presence in the international arena, with overseas revenue growing at a CAGR of 23.71% from 2020 to 2023 [17]

Core Viewpoint - The company, Kaili Medical, has been investing in AI technology research for nearly a decade, resulting in the development of multiple AI-enabled products that enhance diagnostic accuracy and efficiency in medical devices [1][2]. Group 1: AI Technology Integration - Kaili Medical's AI strategy focuses on integrating AI into medical devices rather than pursuing standalone "AI+" or "Internet+" models, ensuring that AI enhances ultrasound and endoscopy equipment [1]. - The S-Fetus technology, developed by Kaili Medical, is the first domestic deep learning-based obstetric ultrasound detection technology, achieving a standard plane recognition rate of over 90% and reducing examination time by 50% [2]. Group 2: Clinical Impact - Early detection of gastrointestinal tumors significantly increases survival rates, with over 90% for early-stage patients, while late-stage patients have survival rates below 25% [2]. - The AI endoscope developed by Kaili Medical functions similarly to a GPS, guiding doctors and providing alerts to improve diagnostic accuracy and reduce missed diagnoses [3]. Group 3: Product Development - Kaili Medical plans to launch a new series of products featuring the iEndo® medical endoscope system platform, which utilizes an innovative multi-core heterogeneous imaging architecture for enhanced computational capabilities [3].